Synadrin (prenylamine lactate) is well established in the long-term management and prophylaxis of angina pectoris. It moderates the cardiac effects of sympathetic stimulation by decreasing the uptake of noradrenaline at the sympathetic nerve endings in the myocardium, and by slowing calcium transport through the endoplasmic reticulum.
Extensive clinical investigation and usage has shown Synadrin to have beneficial effects in angina within a narrow dosage range and without frequent or troublesome side-effects.
BaumingerB BMcMurrayWWaltersG (1970) The effect of oral prenylamine on the excretion of catecholamine metabolites and on the response to tyramine. Clinico-pharmacological and Therapeutical Aspects of Prenylamine, 2nd International Symposium on Prenylamine, Capri, 46.
3.
BraaschWFleckD (1961) Die Beeinflussung von Coronardurchblutung und Sauerstoffversorgung des Herzmuskels durch N' (3'-phenyl-propyl (2'))-1, 1-diphenyl-propyl- (3)-amin. Arzneimittel-Forschung, 11, 336.
4.
BraunsteinerHSailerSSandhoferF (1965) Die Wirkung von phenyl-propyl-diphenylamin auf die Konzentration der freien Fettsäuren im Plasma des Menschen. Klinische Wochenschrift, 43, 355.
5.
CarlssonAWaldeckB (1968) On the mechanism of action of prenylamine on tissue monoamines. Biochimica Applicata, 14, supp. 1, 41.
6.
CardoeN (1968) Prenylamine lactate (Synadrin) in patients with angina pectoris. British Journal of Clinical Practice, 22, 299.
7.
CardoeN (1970) A 2-year study of the efficacy and tolerability of prenylamine in the treatment of angina pectoris. Postgraduate Medical Journal, 46, 708.
8.
CharlierR (1971) Anti-anginal Drugs. Handbook of Experimental Pharmacology, XXXI, (Springer Verlag). Berlin, Heidelberg, New York.
9.
CloarecM (1971) The action of prenylamine (Synadrin; Segontin) on coronary disease. A prolonged, objective evaluation. Clinical Trials Journal, 8, supp. 1, 43.
10.
DaviesA (1971) The “overlap” method of comparing drugs. Practitioner, 207, 90.
11.
DenglerH JEkhelbaumMSchomerusM (1970) The pharmacokinetics of prenylamine. Clinico-Pharmacological and Therapeutical Aspects of Prenylamine, 2nd International Symposium on Prenylamine, Capri, 26.
12.
DonatKSchlosserG A (1966) Zur Problematik der Angina-pectoris Therapie. Medizinische Klinik, 61, 352.
13.
Editorial (1969) Management of coronary artery disease. British Medical Journal, 1, 37.
14.
EysenckH J (1968) The effect of prenylamine on various psychological tasks and emotional responses. Biochemical Aspects of Prenylamine, Biochimica Applicata, 14, supp. 1, 111.
15.
FleckensteinADoringH JGrünGKammermeierH (1968) Influence of prenylamine on the utilization of high energy phosphates in cardiac muscle. Biochemical Aspects of Prenylamine, Biochimica Applicata, 14, supp. 1, 323.
16.
CaddieJSkinnerC (1972) Risk with beta-blocking in bronchial asthma. British Medical Journal, 1, 749.
17.
GaffneyT EBraunwaldE (1963) Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. American Journal of Medicine, 34, 320.
18.
HasselbachWBalzerHMakinoseM (1968) The inhibition of the sarcoplasmic calcium pump by prenylamine, reserpine, chlorpromazine and imipramine. Biochimica Applicata, 14, supp. 1, 297.
19.
HodgeR L (1969) Investigation of a possible beta-blocking action of prenylamine in man. Australian Journal of Experimental Biology and Medical Science, 47, 651.
20.
IversenL L (1967) The uptake and storage of noradrenaline in sympathetic nerves. Cambridge University Press (London).
21.
KappertA (1965) Doppelblindversuch mit hochdosiertem Segontin bei Stenokardie. Zeitschrift für Therapie, 3, 82.
22.
LinderE (1971) The pharmacology of prenylamine. Clinical Trials Journal, 8, supp. 1, 6.
23.
MikkelsenE (1971) Prenylamin (Segontin) i den profylaktiske angina pectoris behandling. Ugeskrift for Laeger, 133, 873.
24.
NaylorW G (1968) Biochemical aspects of prenylamine action, preliminary communication. Biochemical Aspects of Prenylamine, Biochimica Applicata, 14, supp. 1, 305.
25.
NeumannMLuisadaA A (1964) Effect of rapid- and slow acting “coronary” drugs on precordial pain of the aged. American Journal of the Medical Sciences, 247, 156.
26.
NielsenK COwmanC (1967) Differential amine depletion from cardiac adrenergic nerves by Segontin. Experimenta, 23, 203.
27.
ObianwuH O (1965) The effect of prenylamine (Segontin) on the amine levels of brain, heart and adrenal medulla in rats. Acta Pharmacologica et Toxicologica, 23, 383.
28.
PrimeF J (1973) Account of a limited trial of prenylamine in asthmatic patients. In press.
29.
de SchaepdryverA F (1970) Prenylamine and urinary catecholamine excretion during physical exercise. Clinico-pharmacological and Therapeutical Aspects of Prenylamine. 2nd International Symposium on Prenylamine, Capri, 62.
30.
SchmidE (1968) Studies on the mode of action of prenylamine (Segontin) and other coronary dilating drugs in man. Indian Heart Journal, 20, 133.
31.
SchmidtH A EHäusslerAHoffmannW (1963) Resorption, Verteilung und Ausscheidung von 14C-markiertem N-(3'-phenyl-propyl-(2'))-1, 1-diphenyl-propyl-(3) amin (Lactat). Arzneimittel-Forschung, 13, 173.
32.
SchöneH HLindnerE (1960) Die Wirkung des N-(3'-phenyl-propyl-(2'))-1, 1-diphenyl-propyl-(3) amins auf den Stoffwechsel von Serotonin und Noradrenalin. Arzneimittel-Forschung, 10, 583.
33.
SepahaG CJainS RJainP (1971) The treatment of angina pectoris: a double-blind study of prenylamine (Synadrin: Segontin). Clinical Trials Journal, 8, 3, 43.
34.
SowtonG EFitzgeraldJ D (1969) Cardiovascular drug evaluation (2) the assessment of antianginal drugs. In: HarrisE LFitzgeraldJ D (Eds). Principles and Practice of Clinical Trials. E & S Livingstone, Edinburgh and London1970.
35.
StokerJ B (1968) Effect of prenylamine in angina pectoris. British Journal of Clinical Practice, 22, 384.
36.
WinsorT (1971) A double-blind, double cross-over trial of prenylamine in angina pectoris. American Heart Journal, 82, 43.
37.
YoudimM B-HSandlerM (1968) The effect of prenylamine on monoamine oxidase. Biochemical Aspects of Prenylamine, Biochimica Applicata, 14, supp. 1, 175.
